Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Allovir, Inc. | Chief Medical Officer | Common Stock | 454K | $304K | $0.67 | Oct 4, 2021 | Direct |
Forma Therapeutics Holdings, Inc. | EVP, Research & Development | Common Stock | 0 | $5.05 | Oct 14, 2022 | Direct | |
Forma Therapeutics Holdings, Inc. | EVP, Research & Development | Stock Option (Right to Buy) | 0 | Oct 14, 2022 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
FMTX | Forma Therapeutics Holdings, Inc. | Oct 14, 2022 | 2 | $0 | 4 | Oct 14, 2022 | EVP, Research & Development |
FMTX | Forma Therapeutics Holdings, Inc. | Jul 11, 2022 | 2 | $0 | 4 | Jul 12, 2022 | EVP, Research & Development |
FMTX | Forma Therapeutics Holdings, Inc. | Jul 11, 2022 | 0 | $0 | 3 | Jul 12, 2022 | EVP, Research & Development |
ALVR | Allovir, Inc. | Oct 4, 2021 | 4 | -$447K | 4 | Oct 5, 2021 | Chief Medical Officer |
ALVR | Allovir, Inc. | Sep 28, 2021 | 1 | -$90.4K | 4 | Sep 29, 2021 | Chief Medical Officer |
ALVR | Allovir, Inc. | Apr 5, 2021 | 4 | -$897K | 4 | Sep 20, 2021 | Chief Medical Officer |